SCHEMBL5153251

SCHEMBL5153251

COC(=O)c1ccc([C@@H]2C[C@H](NS(=O)(=O)c3cccc4c(N(C)C)cccc34)CN2C(=O)OC(C)(C)C)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 10/20 0.46
HTR6 P50406 1/20 0.40
NR1H2 P55055 2/20 0.39
NR1H3 Q13133 1/20 0.39
HTR1A P08908 4/20 0.38
BRD4 O60885 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
THPO P40225 1/20 0.37
MTOR P42345 1/20 0.37
RAB9A P51151 1/20 0.37
HIF1A Q16665 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.36
GMNN O75496 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150263 0.82 NR1H2 (0.46) NR1H2NR1H3
SCHEMBL5153734 0.80 L3MBTL1 (0.42) NR1H2NR1H3
SCHEMBL5153277 0.76 PDE4B (0.42) NR1H2NR1H3CYP3A4CYP2C19MAPT
SCHEMBL5152868 0.76 PDE4B (0.42) NR1H2NR1H3CYP3A4CYP2C19MAPT
SCHEMBL5186551 0.75 HTR4 (0.39) HTR4HTR1ABRD4
SCHEMBL5153880 0.75 PDE4B (0.44) NR1H2NR1H3RAB9AALDH1A1LMNA
SCHEMBL5153357 0.75 PDE4B (0.44) NR1H2NR1H3CYP3A4CYP2C19
SCHEMBL6542920 0.75 PDE4B (0.40) NR1H2NR1H3
SCHEMBL5150005 0.74 PDE4B (0.44) NR1H2NR1H3CYP3A4CYP2C19
SCHEMBL5153201 0.74 PDE4B (0.44) NR1H2NR1H3CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 HTR4 973/4885HTR6 3000/4885NR1H2 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.